50090-4383 : Tradjenta 5 mg Oral Tablet, Film Coated
NDC: | 50090-4383 |
Labeler: | A-s Medication Solutions |
Product Type: | Human Prescription Drug |
Drug Name: | Tradjenta |
Dosage Form: | Oral Tablet, Film Coated |
Application #: | NDA201280 |
Rev. Date: |
Appearance:
Markings: | D5; |
Shapes: |
Round |
Colors: |
Red |
Size (mm): | 8 |
Segments: * | 1 |
* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines. |
The above image is provided by the U.S. National Library of Medicine (NLM) and is not part of the official label.
NDC Package Codes:
- 50090-4383-0: 90 TABLET, FILM COATED IN 1 BOTTLE (50090‑4383‑0)
Active Ingredients:
- Linagliptin
Dosage Strength:
- 5 mg
Pharmaceutical Classes:
- Dipeptidyl Peptidase 4 Inhibitor [EPC]
- Dipeptidyl Peptidase 4 Inhibitors [MoA]
Related Products:
Based on records with the same trade name.- 0597-0140 Tradjenta 5 mg Oral Tablet by Boehringer Ingelheim Pharmaceuticals, Inc.
- 55154-0410 Tradjenta 5 mg Oral Tablet, Film Coated by Cardinal Health
NDC QR Code
Scan the QR code below to easily reference this data in the future:< Prev: 50090-4382Next: 50090-4384 >
Related Discussions:
Tradjenta and panic attacks
Has anyone experienced panic attacks or extreme anxiety while using tradjenta? My husband had an anxiety attack within 2... 2 replies
Has anyone experienced panic attacks or extreme anxiety while using tradjenta? My husband had an anxiety attack within 2... 2 replies
trajenta linagliptin
what is deference between istamet and trajenta and side effects...
what is deference between istamet and trajenta and side effects...
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.